Breast cancer
Dr Smith speaks with ecancertv at the 2016 San Antonio Breast Cancer Symposium about results from the IBIS-1 trial of tamoxifen as a chemopreventive treatment for women at higher risk of developing breast cancer.
He notes a significant rate of discontinuation of therapy from women experiencing natural symptoms of menopause, which might be mistaken for side effects of the tamoxifen.
Dr Smith considers room for improvement communication to clarify potential outcomes and risks for trial patients.
Breast cancer
Cancer in emergencies: What can we do better to protect the most vulnerable?
Grand Rounds: Improving quality of patient-centred care
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Supporting breast cancer patients in Vietnam
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
Lung cancer screening and treatment in the Philippines
Advancing breast cancer diagnosis in the developing world
Novel antibody-drug conjugates (ADCs) technologies for management of mBC